United Therapeutics Corporation
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $213.36
- Today's High:
- $217.65
- Open Price:
- $214.52
- 52W Low:
- $201.65
- 52W High:
- $283.09
- Prev. Close:
- $213.48
- Volume:
- 384352
Company Statistics
- Market Cap.:
- $10.00 billion
- Book Value:
- 109.708
- Revenue TTM:
- $1.98 billion
- Operating Margin TTM:
- 49.74%
- Gross Profit TTM:
- $1.78 billion
- Profit Margin:
- 36.76%
- Return on Assets TTM:
- 10.52%
- Return on Equity TTM:
- 15.66%
Company Profile
United Therapeutics Corporation had its IPO on 1999-06-17 under the ticker symbol UTHR.
The company operates in the Healthcare sector and Biotechnology industry. United Therapeutics Corporation has a staff strength of 985 employees.
Stock update
Shares of United Therapeutics Corporation opened at $214.52 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $213.36 - $217.65, and closed at $217.22.
This is a +1.75% increase from the previous day's closing price.
A total volume of 384,352 shares were traded at the close of the day’s session.
In the last one week, shares of United Therapeutics Corporation have increased by +1.46%.
United Therapeutics Corporation's Key Ratios
United Therapeutics Corporation has a market cap of $10.00 billion, indicating a price to book ratio of 2.8015 and a price to sales ratio of 6.7594.
In the last 12-months United Therapeutics Corporation’s revenue was $1.98 billion with a gross profit of $1.78 billion and an EBITDA of $1.04 billion. The EBITDA ratio measures United Therapeutics Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, United Therapeutics Corporation’s operating margin was 49.74% while its return on assets stood at 10.52% with a return of equity of 15.66%.
In Q1, United Therapeutics Corporation’s quarterly earnings growth was a negative -3.4% while revenue growth was a positive 9.7%.
United Therapeutics Corporation’s PE and PEG Ratio
- Forward PE
- 14.5349
- Trailing PE
- 14.5521
- PEG
- 1.0244
Its diluted EPS in the last 12-months stands at $14.67 per share while it has a forward price to earnings multiple of 14.5349 and a PEG multiple of 1.0244. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into United Therapeutics Corporation’s profitability.
United Therapeutics Corporation stock is trading at a EV to sales ratio of 5.8955 and a EV to EBITDA ratio of 11.101. Its price to sales ratio in the trailing 12-months stood at 6.7594.
United Therapeutics Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.35 billion
- Total Liabilities
- $324.60 million
- Operating Cash Flow
- $-221100000.00
- Capital Expenditure
- $41.30 million
- Dividend Payout Ratio
- 0%
United Therapeutics Corporation ended 2023 with $6.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.35 billion while shareholder equity stood at $5.12 billion.
United Therapeutics Corporation ended 2023 with $0 in deferred long-term liabilities, $324.60 million in other current liabilities, 700000.00 in common stock, $5.28 billion in retained earnings and $0 in goodwill. Its cash balance stood at $1.16 billion and cash and short-term investments were $2.86 billion. The company’s total short-term debt was $0 while long-term debt stood at $800.00 million.
United Therapeutics Corporation’s total current assets stands at $3.19 billion while long-term investments were $1.77 billion and short-term investments were $1.70 billion. Its net receivables were $134.50 million compared to accounts payable of $239.70 million and inventory worth $102.50 million.
In 2023, United Therapeutics Corporation's operating cash flow was $-221100000.00 while its capital expenditure stood at $41.30 million.
Comparatively, United Therapeutics Corporation paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $217.22
- 52-Week High
- $283.09
- 52-Week Low
- $201.65
- Analyst Target Price
- $281.18
United Therapeutics Corporation stock is currently trading at $217.22 per share. It touched a 52-week high of $283.09 and a 52-week low of $283.09. Analysts tracking the stock have a 12-month average target price of $281.18.
Its 50-day moving average was $220.45 and 200-day moving average was $238.18 The short ratio stood at 3.1 indicating a short percent outstanding of 0%.
Around 175.9% of the company’s stock are held by insiders while 9892.5% are held by institutions.
Frequently Asked Questions About United Therapeutics Corporation
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.